HTR3A and neuroblastoma: In line with the in vivo cell cycle progression experiments, we managed to inhibit the proliferation rate of HTR3Ahigh neuroblastoma cells with a specific HTR3A agonist, which might be developed into a potential therapeutic strategy, especially in a combination with differentiation-inducing drugs69–71.